We’re a close-knit team, dedicated to providing outstanding service to clients, candidates and stakeholders. Our experience and industry knowledge are well regarded in the life science sector, where we have established a reputation for clarity and sound advice. PiR is a positive, informed and supportive environment for clients, candidates and staff, and a place where good ideas grow.
Carolyn founded PiR in response to the industry’s need for flexible, knowledgeable and trusted recruitment services for early stage and mid-capped life science companies. Under Carolyn’s leadership, PiR has developed an impressive network of Executive and Non-Executive leaders with medical, commercial and financial expertise. She has built a company that truly understands the role that outstanding talent plays in supporting early stage businesses as they develop and monetise their products and services. In November 2016 Carolyn became Non-Executive Chair as part of the company’s succession planning.
Sally is known for bringing fresh ideas, energy and drive to business and excels at understanding client and candidate expectations. Under Sally’s leadership, PiR has grown from the new relationships she has fostered with her team. Sally’s collaborative and pragmatic leadership style encourages individualism and team based success, ensuring the best solutions and outcomes for clients and candidates alike. With encouragement from Sally, PiR has broadened its services to include Interim Management, Executive Search and Talent Mapping across all life science functions and geographies.
Nicola is a key member of the PiR management team, responsible for Operations, IT, HR, Facilities, Marketing, Legal and Finance. Overseeing the client team, Nicola ensures that business strategy is implemented and due diligence and process is followed. Her focus, determination, work ethic and insight make her the ideal operations leader for our fast paced and customer-centric business. Nicola has worked in operations for over a decade and prior to this was in management at a global retail brand.
Paul has been with PiR since 2012 and as Senior Executive Researcher, works on executive search projects for our clients. He is renowned for his calm and tenacious approach, leaving nothing to chance and delivering outstanding shortlists for client projects. Clients, candidates and colleagues value his deep understanding of the life science sector and his ability to forge strong relationships. Paul has supported clients in start-ups, SMEs and multi-national pharmaceutical, biotechnology, diagnostic and medical device organisations. He graduated from the University of Northampton with a first class BA (Hons) Degree in Business Management.
Jo joined PiR in 2016, with responsibility for Interim Management. A major part of Jo’s role is to stay in contact with highly qualified, first-in-class professionals, gaining essential industry insight and intelligence. She builds rapport quickly and enjoys the ongoing aspect of building her industry knowledge at networking events. Jo has delivered interim projects for start-ups, SMEs and multinationals in pharmaceutical, biotechnology, diagnostic and medical device organisations. Committed to ongoing personal development, Jo recently achieved her REC accreditation. She is a graduate of Loughborough University.
Maureen has amassed over 30 years’ experience within the life science sector, mainly with GlaxoSmithKline finishing as VP Global Strategy Development for GSK. Since 2007 she has been working with a number of investor-backed companies including as founding Chief Executive of NovaThera, a regenerative medicine spin-out from Imperial College London, and as Non-Executive Director and Chairman of life science spin-out companies from Oxford, Kings College Universities and other life science entrepreneurs.
She is a founding Director of MedInnovate Ltd, a technology consultancy spanning the healthcare industry. She is currently Chairman of Parafricta Ltd, a wound care specialist materials company, and CN Bio Innovations – the human organ-on-a-chip technology company whose LiverChip® and Quantum B® human liver models are being well received as a disruptive route to liver modelling for Hepatitis B and NASH drug discovery, and ADME tox testing. She was a founding industry consulting partner at Kinapse Ltd.
Maureen brings a wealth of sector relevant knowledge and contacts and experienced leadership in developing early stage life science businesses and Big Pharma.
Mark obtained his PhD in pharmacology from Cambridge University and then developed novel 3D tissue culture models, as an academic at the University of Basel until 1992. He has over 25 years’ experience in the discovery of novel treatments for diseases with unmet medical need.
Mark formerly worked at Pfizer where he was responsible for research into neurodegenerative diseases. In 1997, Mark set up Cambridge Drug Discovery as Chief Executive, which was then sold to BioFocus (now part of Charles River) in 2001. Since then, Mark has worked with many early-stage biotechnology companies from foundation through to trade sale or transition onto the public markets. More recently, he was Chief Executive of the Life Sciences Organisation of UK Trade & Investment, which helped UK-based Life Sciences companies raise investment and export overseas. Mark is currently Chief Executive of Cellesce as well as Chairman of NuVision Biotherapies, Ubiquigent and Talisman Therapeutics.
Mark has a background in early stage medtech companies, supporting them from start up to successful exit via trade sale and flotation. Most recently he has held various roles as Chairman or CEO of high potential medtech start-ups and he chairs a panel of the NIHR i4i translational funding scheme for the advancement of healthcare technologies for NHS patients. He began his career as a chartered mechanical engineer before joining the medical device start-up, Medic-Aid Ltd, where, as CEO, he led the company to a management buyout and subsequently listing on the Main Market of the London Stock Exchange before completing a trade sale to Respironics Inc. Since selling his business he has chaired several medtech start-ups and he successfully sold Nigaard Pharma A/S to Zambon Spa in 2015.
Chris is well known amongst the early stage investor and board communities, particularly for his work with Oxford Spinout Equity Management (OSEM), where he invested £12m in university spinouts, returning £40m to the university and growing the overall value of the equity portfolio. Prior to this he held senior roles at Glaxo and GlaxoWellcome for over 23 years, including leadership of the development teams behind major novel therapies (including Imigran, Zofran and Relenza). He also served as a member of the Corporate Strategy Team in a period of significant organisational change. In 2001, he joined Imperial College London to assist the new Vice Chancellor, Sir Richard Sykes, in a variety of ways including strategic planning, complex project management, the commercialisation of science and leadership of the Communications Team. He has a PhD in Biochemistry and post-doctoral research experience in the use of oncofoetal antigens as markers of cancer presence or abnormal placental function.